Holen Sie sich die Stockscreener-App
10.15
3.66%
-0.43
Alumis Inc Aktie (ALMS) Neueste Nachrichten
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population - Yahoo Finance
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com Canada
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff? - stocktwits.com
Price-Driven Insight from (ALMS) for Rule-Based Strategy - Stock Traders Daily
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven DiseasesSlideshow (NASDAQ:ALMS) 2026-09-04 - Seeking Alpha
Alumis to Participate in Upcoming September Investor Conferences - The Manila Times
Four public talks are planned for September. Alumis will stream them online. - Stock Titan
Apple, Tesla, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today's Market -- Barrons.com - moomoo.com
Is Alumis (ALMS) Overvalued After Its 121% One Year Return? - Yahoo Finance
Alumis stock downgraded at Guggenheim (ALMS:NASDAQ) - Seeking Alpha
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy - Yahoo Finance
Guggenheim Downgrades Alumis to Neutral From Buy - marketscreener.com
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair? - Yahoo Finance
Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints - Yahoo Finance
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Canada
Guggenheim downgrades Alumis stock rating after trial miss - Investing.com
Morgan Stanley cuts Alumis stock price target on lupus trial failure By Investing.com - Investing.com South Africa
Alumis (ALMS) Stock Slides As Momentum Traders Refocus On Fundamentals - timothysykes.com
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says - marketscreener.com
This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Oppenheimer Adjusts Price Target on Alumis to $37 From $55, Maintains Outperform Rating - marketscreener.com
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com Australia
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com
Wells Fargo cuts Alumis stock price target on SLE trial results By Investing.com - Investing.com South Africa
Alumis stock plunges 57% after lupus drug trial fails, but psoriasis drug progress continues. - Pluang
Alumis plunges 57% after trial failure; Enovis falls 16% on robotics acquisition news - Pluang
Alumis shares plunge after lupus trial failure, but drug potential remains uncertain - Pluang
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside (NASDAQ:ALMS) - Seeking Alpha
Alumis Plunges 56% After Lupus Drug Fails Key Trial Goals - finance.biggo.com
Alumis’ TYK2 drug fails in key lupus study - BioPharma Dive
Alumis Shares Plummet 59% After Lupus Study Failure Wipes Out $1.67 Billion - TechStock²
Alumis stock tumbles 55% after lupus drug trial misses goals By Investing.com - Investing.com Nigeria
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise - Yahoo Finance
Why Is Alumis Stock Falling Tuesday? - Benzinga
Alumis Announces Topline Phase 2b Results for Envudeucitinib in Systemic Lupus Erythematosus - Kalkine Media
Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward' - Endpoints News
Alumis falls after trial setback for lead drug (ALMS:NASDAQ) - Seeking Alpha
Why is Alumis stock collapsing today? By Investing.com - Investing.com Australia
Alumis Phase 2b lupus trial misses primary and secondary endpoints - Yahoo Finance
ALMS Stock Slides As Losses Mount Despite Strong Cash - StocksToTrade
Alumis stock tumbles 55% after lupus drug trial misses goals - Investing.com
Alumis Reports Mixed Phase 2b LUMUS Results for Envudeucitinib in SLE, Highlights IFNGS-High Subgroup and Safety Data - Quiver Quantitative
Alumis' lupus drug fails mid-stage trial goal - marketscreener.com
Trading Systems Reacting to (ALMS) Volatility - Stock Traders Daily
Alumis (NASDAQ:ALMS) Shares Down 7.9%What's Next? - MarketBeat
What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders - simplywall.st
Equities Analysts Set Expectations for Alumis Q3 Earnings - MarketBeat
H.C. Wainwright reiterates Alumis stock rating at neutral, $25 target - Investing.com
Venture investor’s big move: Latigo Biotherapeutics (ALMS) lands new 14.5% holder - Stock Titan
ALMSAlumis Inc Forecast, Target Price - Finviz
Alumis (NASDAQ:ALMS) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Alumis' (ALMS) "Neutral" Rating Reaffirmed at HC Wainwright - MarketBeat
Alumis (NASDAQ:ALMS) Shares Gap Down After Earnings Miss - MarketBeat
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):